Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers

The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57....

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 73; no. 12; pp. 1545 - 1551
Main Authors PICHON, M. F, BROET, P, ASSELAIN, B, MAGDELENAT, H, DELARUE, J. C, SPYRATOS, F, BASUYAU, J. P, SAEZ, S, RALLET, A, COURRIERE, P, MILLON, R
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing Group 01.06.1996
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( > or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P < 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P < 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P < 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision.
AbstractList The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( > or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P < 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P < 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P < 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision.
The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( &gt; or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P &lt; 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P &lt; 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P &lt; 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision.
Author BROET, P
MAGDELENAT, H
MILLON, R
DELARUE, J. C
SPYRATOS, F
PICHON, M. F
BASUYAU, J. P
SAEZ, S
RALLET, A
COURRIERE, P
ASSELAIN, B
AuthorAffiliation Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, Paris, France
AuthorAffiliation_xml – name: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, Paris, France
Author_xml – sequence: 1
  givenname: M. F
  surname: PICHON
  fullname: PICHON, M. F
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 2
  givenname: P
  surname: BROET
  fullname: BROET, P
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 3
  givenname: B
  surname: ASSELAIN
  fullname: ASSELAIN, B
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 4
  givenname: H
  surname: MAGDELENAT
  fullname: MAGDELENAT, H
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 5
  givenname: J. C
  surname: DELARUE
  fullname: DELARUE, J. C
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 6
  givenname: F
  surname: SPYRATOS
  fullname: SPYRATOS, F
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 7
  givenname: J. P
  surname: BASUYAU
  fullname: BASUYAU, J. P
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 8
  givenname: S
  surname: SAEZ
  fullname: SAEZ, S
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 9
  givenname: A
  surname: RALLET
  fullname: RALLET, A
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 10
  givenname: P
  surname: COURRIERE
  fullname: COURRIERE, P
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
– sequence: 11
  givenname: R
  surname: MILLON
  fullname: MILLON, R
  organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3119524$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/8664127$$D View this record in MEDLINE/PubMed
BookMark eNpVkc1rFDEYxkOp1G3tzauQg3jqrPmYZJKLUIrWQkEPeg6ZzJt1SjYZk5kW_3sz7LLoKR_Pj-fJm-cSnccUAaG3lGwp4epj_-S2VGu5ZZqeoQ0VnDVUse4cbQghXUM0I6_RZSlP9aiJ6i7QhZKypazbIPM9p11MZR4dfrZhAZw8LjPkNA44g4NpTrlg6-sVDinumrrZY59CSC_NMq04Y6LDaYJs-wC4z2DLjJ2NDnJ5g155GwpcH9cr9PPL5x93X5vHb_cPd7ePjWu1nhthqaNkUIMArnhLpZJaArFeaGGJ7xwF6XvZE8e55K0iqndDHZrazgrtBb9Cnw6-09LvYXAQ52yDmfK4t_mPSXY0_ytx_GV26dkw0rWipdXgw9Egp98LlNnsx-IgBBshLcV0itK2TlrBmwPociolgz-FUGLWQkwtxKyFmFpIxd_9-7ATfGyg6u-Pui3OBp_rv43lhHFKtWBtxfABi3ZeMpz0mrVGrUl_AR1ToS8
CODEN BJCAAI
CitedBy_id crossref_primary_10_1016_j_hoc_2007_03_009
crossref_primary_10_1186_bcr1639
crossref_primary_10_1002__SICI_1097_0320_19990415_38_2_61__AID_CYTO3_3_0_CO_2_X
crossref_primary_10_1002_jso_22120
crossref_primary_10_5858_2002_126_0325_MSOERN
crossref_primary_10_1097_PPO_0b013e3181ce4ae1
crossref_primary_10_1097_00000658_200201000_00003
crossref_primary_10_2217_14796694_4_1_15
crossref_primary_10_1046_j_1440_1827_2003_01441_x
crossref_primary_10_1111_j_0006_341X_2001_00844_x
crossref_primary_10_1186_1471_2105_9_63
crossref_primary_10_1002_1097_0215_20000915_87_6_860__AID_IJC16_3_0_CO_2_Y
crossref_primary_10_1016_S0959_8049_02_00067_9
crossref_primary_10_1016_S1607_551X_08_70146_3
crossref_primary_10_1007_s10549_011_1564_5
crossref_primary_10_1038_sj_bjc_6690389
crossref_primary_10_1038_sj_onc_1210269
crossref_primary_10_1016_j_critrevonc_2007_11_004
crossref_primary_10_1177_172460080301800102
crossref_primary_10_1016_S1741_8372_04_02459_4
crossref_primary_10_1038_modpathol_3800229
crossref_primary_10_1148_radiol_2462070169
crossref_primary_10_1186_bcr1631
crossref_primary_10_1089_jwh_1996_5_505
crossref_primary_10_1177_172460080201700103
crossref_primary_10_5812_ircmj_23038v2
crossref_primary_10_1038_modpathol_3800255
crossref_primary_10_1080_07357900801891628
crossref_primary_10_1158_1078_0432_CCR_08_1763
crossref_primary_10_1054_brst_2000_0171
crossref_primary_10_1007_s10549_010_0998_5
crossref_primary_10_1038_sj_bjc_6600335
crossref_primary_10_1080_02841860310004724
crossref_primary_10_1023_A_1006011328655
crossref_primary_10_1186_s13000_023_01433_6
crossref_primary_10_1016_S0889_8588_05_70058_7
crossref_primary_10_1158_0008_5472_CAN_07_2822
crossref_primary_10_1074_jbc_M109_078212
crossref_primary_10_1158_0008_5472_CAN_04_3953
crossref_primary_10_1186_bcr2158
crossref_primary_10_1080_01443610600984669
crossref_primary_10_1002_cncr_11294
crossref_primary_10_1016_j_jcpa_2014_04_001
crossref_primary_10_1177_172460080101600108
crossref_primary_10_1200_JCO_2009_26_4200
crossref_primary_10_1016_j_prp_2009_12_003
crossref_primary_10_1210_er_2010_0016
crossref_primary_10_2217_17520363_2_2_181
crossref_primary_10_1016_j_breast_2014_01_007
crossref_primary_10_1016_S0925_4439_00_00014_4
crossref_primary_10_1111_vco_12795
crossref_primary_10_1007_s10549_008_0110_6
crossref_primary_10_1002_cncr_22381
crossref_primary_10_1023_A_1006141703224
crossref_primary_10_1159_000336539
crossref_primary_10_1200_JCO_2007_12_2747
crossref_primary_10_1001_jamanetworkopen_2021_14904
crossref_primary_10_1016_S1068_607X_00_00021_4
crossref_primary_10_1186_s12957_015_0582_x
crossref_primary_10_3390_ijms21020511
crossref_primary_10_1038_sj_bjc_6690249
crossref_primary_10_1016_j_steroids_2012_02_013
crossref_primary_10_1016_j_jmva_2004_02_009
crossref_primary_10_1002_1097_0142_20010715_92_2_249__AID_CNCR1316_3_0_CO_2_P
crossref_primary_10_3389_fonc_2020_00617
crossref_primary_10_1002_jso_10264
crossref_primary_10_1111_j_1445_1433_2004_03215_x
crossref_primary_10_2460_javma_235_4_391
crossref_primary_10_4103_jomt_jomt_23_20
crossref_primary_10_1023_A_1006046107249
crossref_primary_10_1002_cncr_21262
crossref_primary_10_1016_S0959_8049_96_00531_X
crossref_primary_10_1136_jcp_2005_035550
crossref_primary_10_1007_s10549_010_1153_z
crossref_primary_10_1097_00129039_200609000_00017
crossref_primary_10_1097_COC_0b013e3181967d72
crossref_primary_10_1080_10408360600739218
crossref_primary_10_1002_ijc_10171
crossref_primary_10_1111_j_1439_0531_2011_01816_x
crossref_primary_10_1093_jnci_91_8_728
crossref_primary_10_1007_s10549_010_0746_x
crossref_primary_10_1038_sj_bjc_6690279
crossref_primary_10_1158_1078_0432_CCR_0102_03
crossref_primary_10_1007_s10549_019_05400_y
crossref_primary_10_1002__SICI_1097_0142_19991115_86_10_2083__AID_CNCR28_3_0_CO_2_2
crossref_primary_10_1016_S0025_7753_01_72251_8
crossref_primary_10_1177_8756479318792043
crossref_primary_10_1007_s10549_005_9065_z
crossref_primary_10_1001_jamanetworkopen_2019_18160
crossref_primary_10_1007_s00428_005_0003_6
ContentType Journal Article
Copyright 1996 INIST-CNRS
Copyright_xml – notice: 1996 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.1038/bjc.1996.291
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-1827
EndPage 1551
ExternalDocumentID 10_1038_bjc_1996_291
8664127
3119524
bjc1996291
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID -
-Q-
02
08R
0R
23N
39C
3V.
4.4
53G
55
5GY
5RE
70F
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8R4
8R5
8WZ
A6W
AADWK
AAPBV
AAWBL
AAWTL
AAYJO
AAZLF
ABAWZ
ABDBF
ABDEU
ABFLS
ABGIJ
ABOCM
ABPTK
ABUWG
ACGFS
ACKTT
ACPRK
ADACO
ADBBV
ADBIT
ADHDB
ADQMX
AEDAW
AEJRE
AENEX
AEXYK
AFKRA
AFRAH
AFSHS
AGEZK
AHMBA
AHSBF
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AN0
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBAFP
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BNQBC
BPHCQ
BVXVI
CAG
COF
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EPL
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRJ
FSGXE
FYUFA
GJ
GX1
HCIFZ
HVGLF
HYE
HZ
IH2
J5H
JSO
KQ8
M1P
M41
M7P
NAO
NAPCQ
O9-
OK1
P2P
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q-
Q2X
RIG
RNT
RNTTT
RPM
SNX
SNYQT
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TR2
TUS
UDS
VH1
W2D
WH7
WOW
X7M
XFK
Y6R
ZA5
ZGI
---
.55
.GJ
0R~
36B
406
6J9
AANZL
AATNV
AAUGY
AAYFA
ABLJU
ACBMV
ACBRV
ACBYP
ACGFO
ACIGE
ACRQY
ACTTH
ACVWB
ADFRT
ADMDM
ADYYL
AEFTE
AEVLU
AFNRJ
AGAYW
AGGBP
AGHAI
AI.
AILAN
AJCLW
AJDOV
AMRJV
AMYLF
AOIJS
CCPQU
DNIVK
DPUIP
EMOBN
HZ~
IQODW
IWAJR
JZLTJ
NQJWS
NYICJ
SOHCF
SRMVM
UKHRP
~02
~8M
AACDK
AASML
AAYZH
ABAKF
ABZZP
ACAOD
ACZOJ
AEFQL
AEMSY
AFBBN
AGQEE
AIGIU
CGR
CUY
CVF
ECM
EIF
FIGPU
HMCUK
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c499t-5a1c10d8d5e3834168696e0af595a0f7c1e6fb6b0c33634808bcd1991a7a59f53
IEDL.DBID RPM
ISSN 0007-0920
IngestDate Tue Sep 17 21:24:23 EDT 2024
Fri Aug 16 23:48:54 EDT 2024
Fri Aug 23 02:26:45 EDT 2024
Wed Oct 16 00:47:37 EDT 2024
Sun Oct 29 17:08:25 EDT 2023
Thu Oct 07 19:36:09 EDT 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Human
Mammary gland diseases
Prognosis
Follow up study
Estrogen
Mammary gland
Progesterone
Malignant tumor
Sex steroid hormone
Ovarian hormone
Hormonal receptor
Language English
License CC BY 4.0
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c499t-5a1c10d8d5e3834168696e0af595a0f7c1e6fb6b0c33634808bcd1991a7a59f53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074541/
PMID 8664127
PQID 78114225
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2074541
proquest_miscellaneous_78114225
crossref_primary_10_1038_bjc_1996_291
pubmed_primary_8664127
pascalfrancis_primary_3119524
nature_primary_bjc1996291
ProviderPackageCode ABDEU
AEDAW
AAZLF
-Q-
AADWK
AAYJO
70F
ADQMX
EE.
RNTTT
SWTZT
ABGIJ
RNT
NAO
PublicationCentury 1900
PublicationDate 1996-06-01
PublicationDateYYYYMMDD 1996-06-01
PublicationDate_xml – month: 06
  year: 1996
  text: 1996-06-01
  day: 01
PublicationDecade 1990
PublicationPlace Basingstoke
PublicationPlace_xml – name: Basingstoke
– name: England
PublicationTitle British journal of cancer
PublicationTitleAlternate Br J Cancer
PublicationYear 1996
Publisher Nature Publishing Group
Publisher_xml – name: Nature Publishing Group
References 9192994 - Br J Cancer. 1997;75(12):1854
References_xml
SSID ssj0009087
Score 1.9081442
Snippet The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer...
SourceID pubmedcentral
proquest
crossref
pubmed
pascalfrancis
nature
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1545
SubjectTerms Adult
Aged
Aged, 80 and over
Analysis of Variance
Biological and medical sciences
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Breast Neoplasms - ultrastructure
Female
Follow-Up Studies
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Neoplasm Metastasis
Prognosis
Radioligand Assay
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Risk Factors
Time Factors
Tumors
Title Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers
URI http://dx.doi.org/10.1038/bjc.1996.291
https://www.ncbi.nlm.nih.gov/pubmed/8664127
https://search.proquest.com/docview/78114225
https://pubmed.ncbi.nlm.nih.gov/PMC2074541
Volume 73
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SQEuglPQR6rZJdWiP3rWth-VjCQ1Jy5YcGsjNSLLUbkhssw_69zvjF9mSU84zBjMz0oykb74B-OxTx20uZCwtboHCGhljGpExZmYsFnzlsoy6kRc_1cW1-H4jb_ZAjr0wHWjf2eWsvruf1cs_HbayvXfzESc2v1qcZZj3pEjn-7Cfcz4e0Uem3UT3RJl0B1dkyYB2T7ie21tH3XlqlhXpITzTSolunMyDjDTxab5ozRqtFPrxFo_Vn__DKB_kpfMjeDkUlOxr_-OvYM_Xr-H5YngyfwPl1aohMB2KGTF7e9YERuwIzbJiuN35lubtsG5WOLtr6t8xbdYsYHw0f-NtS-q4GnPWtH5FfVbMEo59wxzFy2r9Fq7Pv_06u4iHqQqxw9PNJpYmdWlS6Up6PJ1iPaZVoXxigiykSULuUq-CVTZxnCsudKKtqwggZXIjiyD5MRzUTe3fAeOVzWjRq0ob4SzqJKaSIhgs8rhTIYIvo2XLtifPKLtHb65L9EVJvijRFxFEvdknLZSSsJOd7HhiUuFEVpeJCD6NnilxZdBzh6l9s12X1EMr0EARHPd-mj4dHB9BvuPASU6U27sSjMSOenuIvPdP_vIDHPa4b7rH-QgHm9XWn2BZs7GnWNBf_jjtgvkfA8T4Zw
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIqAS4l0RoNQHOCabxI8kR1RRLdCtemhRb5HtOLDQJtFuVkj8embyUrfiAuexD8k39oztb74BeOciy00ipC8NboHCaOljGJE-RmZMFlxh45iqkRenan4hPl_Kyx2QYy1MR9q3ZhlUV9dBtfzecSubazsbeWKzs8VRjHFPimh2B-7ieo3leEgftXbDtJfKpFu4LA4HvnvI05n5Yak-TwVxFu3BvVQp0TWUuRGTJkXNh41e438q-wYXf8tAbxMpb0Sm48fwdfymnpDyM9i0JrC_b8k9_vNHP4FHQ67KPvTmp7DjqmdwfzG8xj-H_GxVE08PzYxEwx2rS0bCC_WyYLiTuoZa-bCuDTm7qqtvPsUBVqLr1b_8TUPDcaEnrG7cikq4mCGKfMssueJq_QIujj-eH839oWGDb_Hg1PpSRzYKi7SQDg--mOqlKlMu1KXMpA7LxEZOlUaZ0HKuuEjD1NiCuFc60TIrJd-H3aqu3EtgvDAx7SeqSLWwBseEupCi1Jg_cqtKD96PkOVNr8uRd-_pPM0R5JxAzhFkD7wez2kUWsnY2Q62IJ6GcNLBi4UHhyPkOS46eknRlas365zKcwX-IA_2eweYpg4e5UGy5RmTndS8ty2Id6fqPeD76r9nHsKD-fniJD_5dPrlNez19HK6LnoDu-1q4w4we2rN226t_AGc9Rlq
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagiKpSxbsiQKkPcMzTjyRHVFiVx1Z7oFLFJbIdGxbaJNrNqhK_npm8tFtx6nnGh-Qbe8b2528IeWdjw3TKhS80LIFcK-FDGhE-ZGYoFmxpkgRfI8_P5dkF_3IpLrdafXWkfaOXQXV1HVTLXx23srk24cgTCxfz0wTynuBx2JQuvE8ewJxN0nGjPurtRlkvl4kncXkSDZz3iGWh_m3wjZ4Mkjw-IA8zKXnXVGYrL02qmoeNWsO_cn2Ti_9VobfJlFvZafaY_Bi_qyel_Ak2rQ7M31uSj3f68Cfk0VCz0g-9y1Nyz1bPyP58uJV_TorFqka-HpgpiodbWjuKAgz1sqSwotoGW_rQrh05vaqrnz7mA-ogBOsbf9OgO0z4lNaNXeFTLqqRKt9SgyG5Wr8gF7NP30_P_KFxg29gA9X6QsUmjsqsFBY2wFDyZTKXNlJO5EJFLjWxlU5LHRnGJONZlGlTIgdLpUrkTrAjslfVlX1JKCt1guuKLDPFjQafSJWCOwV1JDPSeeT9CFvR9PocRXevzrICgC4Q6AKA9ojXYzp5gRWNne14B-bJhaEeXsI9cjLCXsDkwxsVVdl6sy7wmS6HH-SRoz4IpqFDVHkk3YmOyY6q3rsWwLxT9x4wfnXnkSdkf_FxVnz7fP71NTnoWeZ4avSG7LWrjT2GIqrVb7vp8g9nIBvq
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+steroid+receptors+after+long-term+follow-up+of+2257+operable+breast+cancers&rft.jtitle=British+journal+of+cancer&rft.au=Pichon%2C+M+F&rft.au=Broet%2C+P&rft.au=Magdelenat%2C+H&rft.au=Delarue%2C+J+C&rft.date=1996-06-01&rft.issn=0007-0920&rft.volume=73&rft.issue=12&rft.spage=1545&rft.epage=1551&rft_id=info:doi/10.1038%2Fbjc.1996.291&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon